Liposomal Anthracyclines: Adjuvant and Neoadjuvant Therapy for Breast Cancer

Liposomal Anthracyclines: Adjuvant and Neoadjuvant Therapy for Breast Cancer Susana Campos Oncologist 2003; 8(Suppl 2): 10-16 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in breast cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the role of conventional anthracyclines in the adjuvant breast cancer setting. Discuss the efficacies and tolerabilities of liposomal anthracyclines as neoadjuvant therapy in patients with locally advanced breast cancer. Explain the rationale for the future study of liposomal anthracyclines as adjuvant therapy for patients with early-stage breast cancer. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Click Here to return to the complete course listing of Liposomal Anthracyclines for Breast Cancer: Clinical Efficacy and Safety Update.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Sept. 18, 2003 Most Recent Review: June 10, 2005* Most Recent Update: Sept. 18, 2003 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.